

25. Shimosato Y. Pulmonary neoplasms. In: Stephen SS, editor. Diagnostic surgical pathology. 3th ed. Vol 1. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. p. 1069–115.
26. Mizutani Y, Nakajima T, Morinaga S, Gotoh M, Shimosato Y, Akino T, *et al.* Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. *Cancer* 1988;61:532–7.
27. Nicholson AG, McCormick CJ, Shimosato Y, Butcher DN, Sheppard MN. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. *Histopathology* 1995;27:57–60.
28. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. In: World Health Organization international classification of tumors. 3rd ed. Berlin, NY: Springer; 1999.
29. Hiraike N, Sohma H, Kuroki Y, Akino T. Epitope mapping for monoclonal antibody against human surfactant protein A (SP-A) that alters receptor binding of SP-A and the SP-A-dependent regulation of phospholipid secretion by alveolar type II cells. *Biochim Biophys Acta* 1995;1257:214–22.
30. Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. *J Histochem Cytochem* 1974;22:1084–91.
31. Alan S, James L. In: Respiratory system. Human histology. 2nd ed. Barcelona, Spain: Mosby; 1997.
32. Linnoila RI, Jensen SM, Steinberg SM. Peripheral airway cell marker expression in non-small cell lung carcinoma. *Am J Clin Pathol* 1992;97:233–43.
33. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. *Histopathology* 2000;36:415–20.
34. Gazdar AF, Bunn PA, Minna JD, Baylin SB. Origin of human small cell lung cancer. *Science* 1985;229:679–80.

Book Review

Bennett JM, editor: *The Myelodysplastic Syndromes: Pathobiology and Clinical Management*, 528 pp, New York, Marcel Dekker, Inc., 2002 (\$165.00).

This is the 27th volume in the Basic and Clinical Oncology series, whose goal is to present new knowledge discovered at the intersection between the laboratory and the clinic. The current, multi-authored book covers diverse facets of the myelodysplastic syndromes (MDS): epidemiology, pathogenesis, diagnosis, prognostic factors, drug resistance, and therapy.

As a diagnostic hematopathologist, I found especially illuminating the discussions of the new World Health Organization classification of hematological malignancies, hypocellular MDS, therapy-related MDS, and juvenile myelomonocytic leukemia in children.

I can imagine that my clinical colleagues will appreciate the chapters on response criteria for MDS, treatment of anemia, and new investigational strategies.

In general, the chapters are succinct and concentrate on the most recent developments in the field. Despite the many contributors (33!), the volume reads well, with an erudite and literary quality. I can recommend it to any pathologist or clinician who regularly attends the American Society of Hematology meeting. It is practical, scholarly, and to the point.

Howard Ratech

*Montefiore Medical Center/Albert Einstein
College of Medicine
Bronx, New York*